Innovative Partnering Models
Pfizer has established a number of novel approaches to work with partners in developing new medicines. Moving beyond traditional collaborations and licensing deals, here are a few examples:
Academic & Start-up Company Partnerships
Pfizer currently supports numerous collaborative partnerships with world-class research institutions such as the University of California, Yale, Penn, the University of Virginia and Peking University, among many others, and is seeking additional opportunities to identify seed-stage investment opportunities to support early-stage technologies as they transition from a pure academic environment into new start-up companies that align with our core research interests. These investments complement our Pfizer Venture Investment activities.
Alternative Development / Funding Models
Pfizer WRD is actively exploring risk and cost sharing approaches to develop WRD as well as external partner programs to enable promising therapies to reach patients. Approaches include partnering WRD assets with pre-defined buy back rights, leveraging non-dilutive funding, and establishing strategic disease area alliances with biopharmaceutical companies and private equity / venture capital groups. Partnerships across the full range of WRD disease areas of interest, which are described in this brochure, will be considered, with a focus on clinical stage programs in particular.
Alternative Development / Funding Models Contact:
Girish Aakalu (Girish.N.Aakalu@pfizer.com)
Centers for Therapeutic Innovation
The Centers for Therapeutic Innovation (CTI) labs were created to establish real-time research partnerships with select academic medical centers. CTI academic research partners work side-by-side with Pfizer scientists in the discovery and development of new therapies for unmet medical needs. Pfizer has opened new CTI labs in San Francisco, New York, Boston, and San Diego. These state-of-the-art laboratories are populated with Pfizer scientists and post-docs exploring opportunities to advance novel antibody therapeutics through preclinical development and first-in-human proof of mechanism studies. Pfizer's Centers for Therapeutic Innovation demonstrate the company's deep commitment to establishing close partnerships with leading academic medical centers to translate ground-breaking research into important new therapies that address key unmet medical needs.
Tony Coyle (Anthony.Coyle@pfizer.com)
Pfizer Venture Investments (PVI)
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, invests in private companies in traditional venture capital syndicates. PVI also uses equity to support novel business structures such as consortium-based technology development (e.g. Ablexis), product out-licensing (e.g. Clovis Oncology) and business spinouts (e.g. Ziarco). Further, PVI invests in funds that offer geographic reach to provide a view into the development of healthcare and life sciences businesses in developing countries such as Africa, Brazil and China. PVI has an interest in working with others to explore new business models that can create value for all players in the healthcare/life sciences ecosystem and ensure the continued development of therapeutics, technologies and services for all those whose medical needs are not being met.
Please visit www.pfizerventureinvestments.com
Barbara Dalton (Barbara.Dalton@pfizer.com)
ERDI Global Scouting
The Global Scouting team is composed of skilled scientists with pharmaceutical and biotechnology research experience, all working to support Pfizer's research interests by scouting for collaborative relationships with both academic and biopharmaceutical partners. These scientists ensure Pfizer is an active participant in regional and international scientific discussions and help R&D work closely with its partners once relationships are established. By working with Pfizer's 100+ country organizations, we have built a strong international scouting network capable of connecting our R&D scientists to innovative opportunities around the world.
The team also directs the investment of a seed fund available to support collaborations with start-up companies founded by experienced entrepreneurs pursuing the commercialization of inventions that benefit patients and which closely align with Pfizer's research interests and portfolio.
Key Regional Contacts:
Yuan-Hua Ding (Yuan-Hua.Ding@pfizer.com))
Australia / NZ
Dan Grant (Daniel.Grant@pfizer.com)
Bettina Hamelin (Bettina.Hamelin@pfizer.com)
Mark Lundie (Mark.Lundie@pfizer.com)
Patrice Roy (Patrice.Roy@pfizer.com)
Nessa Carey (Nessa.Carey@pfizer.com))
Maria Flocco (Maria.Flocco@pfizer.com)
Ajith Kamath (Ajith.V.Kamath@pfizer.com)
Olga Krylova (Olga.Krylova@pfizer.com)
Latin America and South Africa
Gabriela Cezar (Gabriela.G.Cezar@pfizer.com)
Olga Krylova (Olga.Krylova@pfizer.com)
Melissa Fitzgerald (Melissamarie.Fitzgerald@pfizer.com)
Greg Naeve (Gregory.Naeve@pfizer.com)